Bavarian Nordic (BAVA) Stock Overview
Develops, manufactures, and supplies life-saving vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BAVA Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 181.55 |
| 52 Week High | DKK 244.80 |
| 52 Week Low | DKK 123.30 |
| Beta | 1.09 |
| 1 Month Change | -5.44% |
| 3 Month Change | -2.78% |
| 1 Year Change | 8.49% |
| 3 Year Change | 1.94% |
| 5 Year Change | -36.87% |
| Change since IPO | -28.80% |
Recent News & Updates
Recent updates
Bavarian Nordic A/S (CPH:BAVA) Held Back By Insufficient Growth Even After Shares Climb 38%
Jul 28
Earnings Working Against Bavarian Nordic A/S' (CPH:BAVA) Share Price
Jun 13Here's Why Shareholders May Want To Be Cautious With Increasing Bavarian Nordic A/S' (CPH:BAVA) CEO Pay Packet
Apr 03Bavarian Nordic's (CPH:BAVA) Soft Earnings Are Actually Better Than They Appear
Mar 13Bavarian Nordic A/S Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Mar 08
Chikungunya Vaccine Launch And Market Expansion Will Open Opportunities But Mpox Demand Uncertainties Could Pose Risks
The chikungunya vaccine launch and expansion into new markets could significantly drive revenue and broaden customer base.Getting In Cheap On Bavarian Nordic A/S (CPH:BAVA) Is Unlikely
Dec 14Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?
Nov 16Market Participants Recognise Bavarian Nordic A/S' (CPH:BAVA) Earnings Pushing Shares 53% Higher
Aug 26Bavarian Nordic A/S Just Missed Earnings - But Analysts Have Updated Their Models
Aug 25Bavarian Nordic (CPH:BAVA) Seems To Use Debt Quite Sensibly
Aug 09Bavarian Nordic A/S' (CPH:BAVA) Shareholders Might Be Looking For Exit
Jul 11Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts
May 12Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet
Apr 09Shareholder Returns
| BAVA | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -0.6% | 0.5% | -1.3% |
| 1Y | 8.5% | -2.7% | -27.3% |
Return vs Industry: BAVA exceeded the Danish Biotechs industry which returned -2.7% over the past year.
Return vs Market: BAVA exceeded the Danish Market which returned -27.3% over the past year.
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 3.6% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DK Market | 9.0% |
| 10% least volatile stocks in DK Market | 2.9% |
Stable Share Price: BAVA has not had significant price volatility in the past 3 months compared to the Danish market.
Volatility Over Time: BAVA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,692 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | DKK 14.07b |
| Earnings (TTM) | DKK 1.38b |
| Revenue (TTM) | DKK 6.24b |
Is BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | DKK 6.24b |
| Cost of Revenue | DKK 3.17b |
| Gross Profit | DKK 3.07b |
| Other Expenses | DKK 1.70b |
| Earnings | DKK 1.38b |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | 17.75 |
| Gross Margin | 49.20% |
| Net Profit Margin | 22.03% |
| Debt/Equity Ratio | 0.1% |
How did BAVA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 02:19 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bavarian Nordic A/S is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |
| Hakon Hemme Jørgensen | Danske Bank |